Beijing PINS Medical Equipment Co. Ltd. was established in 2008.

As an innovative high-tech enterprise with focus on neuromodulation, PINS Medical has developed a variety of clinical products, which include stimulators for deep brain, vagus nerve, spinal cord, and sacral nerve stimulation therapies. PINS Medical devotes itself to providing cutting-edge treatments for patients who suffer from neurological disorders, such as Parkinson's disease, epilepsy, chronic pain, and uroclepsia.

The name of PINS is derived from a Chinese word with the original meaning of "Magic Pin," the ability to cure disease. PINS is also an abbreviation of "Patient Is No. 1 always." This message clearly represents the goal of PINS Medical for "restoring hope," not simply as an innovation company but also across society to citizens.

www.pinsmedical.com/html/en/ info@pinsmedical.com
PUT HUMAN HEALTH AT THE HEART OF YOUR RESEARCH

Submit your research: cts.ScienceMag.org
VERTEX PHARMACEUTICALS PROVES DRUG DISCOVERY IS THE ULTIMATE TEAM SPORT

Vertex Pharmaceuticals has always championed a culture of innovation, one that empowers its employees to tackle tough problems, pivot toward novel solutions, and tap creative resources in order to help patients. While the company, headquartered in Boston with research sites in San Diego and Oxford, United Kingdom, has numerous projects underway, its main mission for the last several years has been to treat cystic fibrosis (CF), a genetic disease that affects the lungs, liver, gastrointestinal tract, pancreas, sinuses, sweat glands, and reproductive tract. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and inflammation, often resulting in progressive lung damage and eventually leading to death. According to the Cystic Fibrosis Foundation Patient Registry, there are more than 30,000 people in the United States living with CF (and more than 70,000 worldwide), and approximately 1,000 new cases of CF are diagnosed each year.

But CF is only one of several serious diseases that Vertex is working on. And by investing in science and going after the root cause of disease, the company empowers its diverse teams to “make the impossible possible,” says Reshma Kewalramani, Vertex’s chief executive officer and president. “We go after some of the most difficult scientific problems, knowing that our unique approach to drug discovery, coupled with the perseverance and commitment of our team, will get us to solutions that ultimately help patients.”

It starts with picking the right problem

Across all of its R&D programs, Vertex has championed an innovative approach to drug discovery. “It starts with picking the right problems to go after,” says David Altshuler, Vertex’s chief scientific officer. “We only work on diseases where we have a deep understanding of the underlying human biology, validated targets, and biomarkers that translate well from the lab into people. We select diseases for which we believe we can have a transformative impact for patients, not just an incremental benefit. Then we research and develop therapeutic approaches that are most likely to succeed. Rather than looking for problems we can solve with only the tools we’ve used before, we figure out the problems that need to be solved for the diseases we’re going after and invent the tools to fix them.”
This strategy is central to Vertex and has fundamentally shaped the company’s pipeline of R&D programs. It starts with a scientific problem waiting to be solved. "We first 'crack the biology' of a disease, meaning we ensure our biological target plays a causal role in the disease. Then we 'pour on the chemistry or technology' to find potential treatments," says Kewalramani. "We spend a lot of time and effort validating our laboratory assays and clinical biomarkers upfront, which gives us higher confidence that a potential therapy will succeed when we investigate it in the clinic."

Investing in scientific research is clearly where the company is focused. In 2019, 73% of the company’s operating expenses were dedicated to R&D, a disproportionately large amount when compared to the average biotech and pharma companies in the industry. In addition, three out of five employees work in R&D, which Altschuler credits as the most important aspect of drug discovery.

"Discovering potential new medicines is the ultimate team sport," says Altschuler. "It takes hundreds of scientists and researchers working together to bring a new medicine to patients who are waiting."

Team Impossible is on the case

Indeed, "I often refer to our teams as 'Team Impossible,' because no matter how big the challenge, they always find solutions that seem to defy what’s possible," says Kewalramani. "This sense of urgency is incredibly important to the people living with serious diseases."

Vertex spearheads novel systems and processes to foster this velocity and tenacity. For example, in 2015, Vertex became one of the first companies to implement drug product continuous manufacturing (CM) technology in the development and production of its investigational and commercial medicines. With CM, raw materials are added into one continuously running system, and quality control takes place throughout the production process. "Continuous manufacturing results in faster, more streamlined manufacturing process development and scale-up," says Stuart Arbuckle, Vertex’s chief commercial officer. "We’ve successfully integrated this technology into our process development, clinical and commercial supply production processes."

Another way Vertex reduces development timelines is by doing clinical studies and other development activities in parallel, where possible, instead of one at a time. "We’re always looking for ways we can do multiple things at the same time, because having these faster timelines gives us the potential to get medicines to patients quicker, and the sooner we can get medicines to patients the better," explains Carmen Bozic, Vertex’s chief medical officer.

Vertex’s innovations aren’t just happening in the lab or in clinical studies. Nia Tatsis, Vertex’s chief regulatory officer, views the company’s partnerships with regulators as a critical piece of the puzzle. "Part of my goal is to ensure regulations are keeping pace with scientific innovation," she says. "Our science is evolving rapidly, and we need strong working relationships and trust with regulators to achieve our shared goal of bringing new medicines to patients who need them."

None of these advancements would be possible if not for the enterprise’s prime directive: "We have developed a very special, inclusive culture at Vertex," Kewalramani shares. "More than half of our global employees are women and five out of 10 of our directors are diverse on a gender or ethnic basis—and it’s that diversity of thought and experience that ensures we make the best decisions for patients and our business."

To infinity and beyond: Tackling the next set of disease targets

"Our mission is to use scientific innovation to bring treatment options to people with serious diseases. So we’re applying what we’ve learned in CF to a number of other serious diseases in which we understand the causal human biology and have validated targets and biomarkers with high fidelity from bench to bedside, such as sickle cell disease, alpha-1 antitrypsin deficiency, and Duchenne muscular dystrophy," says Kewalramani. "We’re leveraging multiple therapeutic modalities such as cell therapies, gene editing, and mRNA [messenger RNA] therapies."

Vertex continuously asks the following questions: What else can we do to advance medicines? Where else can we apply our research in helping patients? How can we bring medicines to patients faster? By using the power of biology, chemistry, emerging technologies, creativity, and teamwork to address serious diseases, Vertex will continue to pioneer advances in science and medicine in the service of patients who are waiting for them.
DOESN’T YOUR RESEARCH DESERVE THE BEST READERS?

Submit your research: cts.ScienceMag.org
READY FOR A TRULY LIFE-CHANGING MOMENT?
APPLY NOW.

The Science & SciLifeLab Prize for Young Scientists is an annual prize awarded to early-career scientists. The prize is presented in four categories: Cell and Molecular Biology; Genomics, Proteomics, and Systems Biology Approaches; Ecology and Environment; and Molecular Medicine.

As a winner, you will have your essay published by Science, win up to USD 30,000 and be invited to Sweden where you will receive your award, present your research and meet with leading scientists in your field.

Get ready for a life-changing moment in your scientific career – apply now, deadline is July 15!

SCIENCEPRIZE.SCI LifELAB.SE

2019 winners (from left): Longzhi Tan, Zibo Chen, Barbara Klump and Humsa Venkatesh.
2019 Winner
Lauren Orefice, Ph.D.
For research on the causes and potential therapies for autism spectrum disorders

Eppendorf & Science Prize for Neurobiology
The annual Eppendorf & Science Prize for Neurobiology is an annual international prize which honors young scientists for their outstanding contributions to neurobiological research based on methods of molecular and cell biology. The winner and finalists are selected by a committee of independent scientists, chaired by Science’s Senior Editor, Dr. Peter Stern. If you are 35 years of age or younger and doing great research, now is the time to apply for this prize.

As the Grand Prize Winner, you could be next to receive
> Prize money of US$25,000
> Publication of your work in Science
> Full support to attend the Prize Ceremony held in conjunction with the Annual Meeting of the Society for Neuroscience in the USA
> 10-year AAAS membership and online subscription to Science
> Complimentary products worth US$1,000 from Eppendorf
> An invitation to visit Eppendorf in Hamburg, Germany

It’s easy to apply! Write a 1,000-word essay and tell the world about your work. Learn more at:
www.eppendorf.com/prize

Now It’s Your Turn!
Application Deadline
June 15, 2020
下一位获奖者就是您!

Eppendorf & Science 神经生物学奖

您可能就是下一位获奖者，并将获得:
> $25,000 美元奖金
> 获奖论文发表在《Science》杂志上
> 得以全额资助参与美国神经科学协会年会和颁奖仪式
> 10 年 AAAS 会员和《Science》电子期刊赠阅
> 赠送价值 $1,000 美元的 Eppendorf 产品
> 获邀参观位于德国汉堡的 Eppendorf 总部

申请非常容易! 只需撰写一篇 1,000 字左右的论文，来阐述您所从事的研究内容即可。
欲了解更多信息，请登陆:

www.eppendorf.com/prize
Now It’s Your Turn!

Eppendorf & Science Prize for Neurobiology

Eppendorf & Science 神経生物学賞は、分子生物学や細胞生物学に基づく神経生物学研究において、卓越した貢献のあった若手科学者に毎年贈られる国際賞です。最終選出者は、Science 誌の編集主任 Dr. Peter Stern をはじめとする科学者たちの独立委員会によって選出されます。年齢が35歳以下で、素晴らしい研究に従事していらっしゃる方なら、今こそこの賞に挑戦してみてください。

受賞者には下記内容の賞が授与されます:
> 賞金：25,000 US ドル
> Science 誌に研究内容を掲載
> 米神経科学学会年次総会に伴って開催される授賞式への参加を全面サポート
> 10 年間の AAAS 会員資格および Science 誌オンライン購読権
> 1,000 US ドル相当のエッペンドルフ製品を提供
> ドイツ・ハンブルクのエッペンドルフ本社にご招待

応募は簡単です! あなたの研究について 1,000 語の小論文を書いてください。

詳しくはこちら: www.eppendorf.com/prize

申込期限
2020年6月15日
As AAAS’s first multidisciplinary, open access journal, Science Advances publishes research that reflects the selectivity of high impact, innovative research you expect from the Science family of journals, published in an open access format to serve a vast and growing global audience. Check out the latest findings or learn how to submit your research: ScienceAdvances.org

GOLD OPEN ACCESS, DIGITAL, AND FREE TO ALL READERS
Custom Antibodies for Research & Immunotherapy

Antibody Development and Production Services

ProMab Biotechnologies has two decades of experience generating highly specific and potent monoclonal antibodies

- Mouse / Rat Monoclonal Antibody
- Rabbit Monoclonal Antibody
- Human Monoclonal Antibody
- Recombinant Antibody
- Bispecific Antibody
- Antibody Humanization
- Antibody Sequencing
- Stable Cell Line Generation
- Antibody Production

All products are for research only

Discover more | www.ProMab.com

2600 Hilltop Dr, Building B, Suite C320, Richmond, CA 94806
☎ 1.866.339.0871 | ✉️ info@promab.com